Compare · DFTX vs HPCO
DFTX vs HPCO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Hempacco Co. Inc. (HPCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and HPCO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $4.71B.
- Over the past year, DFTX is up 345.2% and HPCO is up 0.0% - DFTX leads by 345.2 points.
- DFTX has hit the wire 6 times in the past 4 weeks while HPCO has been quiet.
- DFTX has more recent analyst coverage (5 ratings vs 0 for HPCO).
PerformanceDFTX+81.53%HPCO+0.00%
2026-06-15+0.00%2026-07-24
- Company
- Definium Therapeutics Inc.
- Hempacco Co. Inc.
- Price
- $43.14+0.54%
- $0.62-11.65%
- Market cap
- $4.71B
- -
- 1M return
- +2.42%
- +0.00%
- 1Y return
- +345.20%
- +0.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 6
- 0
- Recent ratings
- 5
- 0
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
Latest HPCO
- Hempacco Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities
- SEC Form NT 10-Q filed by Hempacco Co. Inc.
- SEC Form DEFA14A filed by Hempacco Co. Inc.
- SEC Form DEF 14A filed by Hempacco Co. Inc.
- Hempacco Co. Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-K filed by Hempacco Co. Inc.
- Hempacco Co. Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing